IMMIX BIOPHARMA, INC. Income (Loss) from Continuing Operations before Income Taxes, Domestic
IMMIX BIOPHARMA, INC. (IMMX) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$29.10 million for the 12-month period ending 2025-12-31, per its 10-K/A filed 2026-03-27.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-27
- IMMIX BIOPHARMA, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$29.10M.
- IMMIX BIOPHARMA, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$20.11M.
- IMMIX BIOPHARMA, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$13.95M, a 280.21% decline from fiscal 2022.
- IMMIX BIOPHARMA, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was $7.74M, a 68.08% decline from fiscal 2021.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$29.10M 10-K/A · filed 2026-03-27 | |
| 2024-12-31 | -$20.11M 10-K/A · filed 2026-03-27 | |
| 2023-12-31 | -$13.95M 10-K · filed 2025-03-25 | $13.95M 10-K · filed 2024-03-29 |
| 2022-12-31 | $7.74M 10-K · filed 2024-03-29 | |
| 2021-12-31 | $24.25M 10-K · filed 2023-03-27 | |
| 2020-12-31 | $952.80K 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |